Enfortumab-vedotin/pembrolizumab combination, ADCs, and targeted therapies reshape metastatic urothelial carcinoma treatment
[Update: Evolution in the management of metastatic urothelial carcinomas].
Background
Metastatic urothelial carcinoma (mUC) has historically presented significant therapeutic challenges, necessitating a rapid evolution in treatment strategies. Traditional approaches often yielded limited survival benefits, prompting the exploration of novel mechanisms. This review highlights the paradigm shift driven by antibody-drug conjugates (ADCs), targeted therapies, and precision medicine, which are now reshaping the standard of care and expanding actionable targets for improved patient outcomes.